Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ID4
REST API REST API
Homo sapiens
ID4 is differentially expressed in 302 experiments: 155 organism parts: liver, bone marrow, ... (153 more);, 220 disease states: normal, prostate carcinoma, ... (218 more);, 98 cell types 448 cell lines 40 compound treatments and 68 other conditions.
Synonyms bHLHb27
Orthologs ID4 (Gallus gallus)   Id4 (Rattus norvegicus)   id4 (Danio rerio)   Id4 (Mus musculus)   emc (Drosophila melanogaster)   ID4 (Canis familiaris)   id4 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term neuroblast proliferation, negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, cell proliferation, positive regulation of cell proliferation, transcription corepressor activity, positive regulation of transcription from RNA polymerase II promoter, G1/S transition of mitotic cell cycle, nucleus, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, brain development, cerebral cortex neuron differentiation, negative regulation of oligodendrocyte differentiation, fat cell differentiation, negative regulation of neuron differentiation, negative regulation of fat cell differentiation, cellular protein localization, hippocampus development, negative regulation of astrocyte differentiation, positive regulation of osteoblast differentiation, central nervous system myelination, RNA polymerase II transcription factor binding
InterPro Term HLH_DNA-bd
UniProt Accession P47928
Search EB-eye ENSG00000172201
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC38
2
E-MTAB-37, E-MTAB-62
HL-60
2
E-GEOD-5258, E-MTAB-37
442 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, ... (47 experiments)

Factor Value U/D Experiments
stromal cell
4
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998, E-GEOD-10797
endothelial cell
2
E-GEOD-3998, E-GEOD-3920
mesenchymal stem cell
1
2
E-GEOD-2248, E-GEOD-9894, E-MEXP-466
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-MEXP-466
cardiac myocyte
1
E-AFMX-5
bronchial epithelial
1
E-MTAB-25
92 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (68 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MTAB-62, E-MTAB-37, E-MEXP-231
prostate carcinoma
1
4
E-MEXP-1327, E-MTAB-62, E-GEOD-96, E-TABM-26, E-MEXP-2034 ... (5 experiments)
uterine fibroid
3
E-MTAB-62, E-GEOD-7307, E-GEOD-2724
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
214 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-5542, E-TABM-868, E-MEXP-1958, E-MEXP-1269, ... (27 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
2
2
E-GEOD-5230, E-MEXP-1269
none
4
5
E-GEOD-5741, E-GEOD-5230, E-GEOD-4600, E-MEXP-2285, E-GEOD-412, ... (9 experiments)
estradiol
1
E-GEOD-20081
FLAP
1
1
E-GEOD-3202
actinomycin D
1
E-GEOD-6400
bacterial endotoxin
1
E-GEOD-3284
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-GEOD-18005, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-215, E-MEXP-1446, E-GEOD-19018, E-GEOD-9764, ... (8 experiments)

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-GEOD-1926, E-MEXP-2069, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-6802

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-TABM-130, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-4600 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-1343

pt
studied in E-GEOD-21653

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.402 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM